stockportfolio.pro
Stocks / ALC vs RPRX
ALC vs RPRX
Alcon Inc. and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alcon Inc. (ALC) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $32.2B | $31.6B |
| Revenue (latest FY) | $10.40B | $2.38B |
| Net income (latest FY) | $980.00M | $770.95M |
| Revenue growth (5y CAGR) | 6.1% | 2.3% |
| Net margin | 9.4% | 32.4% |
| Return on equity | 4.5% | 11.9% |
| P/E ratio | 39.6 | 28.9 |
| Dividend yield | 0.5% | 1.7% |
| Profitable years (of last 10) | 4 | 8 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALC — free Open RPRX — freeFrequently asked questions
Which is bigger, ALC or RPRX?
Alcon Inc. is larger by market capitalization — $32.2B versus $31.6B.
Which grows faster, ALC or RPRX?
Over the last five fiscal years, Alcon Inc. grew revenue faster — 6.1%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.